Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES

ConclusionsIn patients with chronic HCV infection, increasing proton pump inhibitor use is associated with a dose‐dependent risk of progression of chronic liver disease to cirrhosis, as well as an increased risk of hepatic decompensation and hepatocellular carcinoma.

Source: Alimentary Pharmacology and Therapeutics - November 3, 2017 Category: Drugs & Pharmacology Authors: D. K. Li, P. Yan, A ‐B. Abou‐Samra, R. T. Chung, A. A. Butt Tags: ORIGINAL ARTICLE Source Type: research